Introduction: This study aimed to analyze the survival outcomes and adverse events (AEs) associated with the long-term use of tyrosine kinase inhibitors (TKIs) and to assess health-related quality of life (HRQoL) in patients with chronic myeloid leukemia (CML). Methods: Medical records of 345 patients with CML treated with at least one type of TKI were retrospectively reviewed. Results: No significant differences in survival were observed based on the number of different TKIs the patients received (p = 0.301) or the sequence of TKIs used (p = 0.770). Among 182 patients treated with nilotinib, 25 experienced cardiovascular events (CVEs). After 10 years of nilotinib treatment, CVEs occurred in 55.2% of patients with ≥2 vascular risk factors. Pleural effusion was observed in 27 of 78 dasatinib-treated patients. In terms of HRQoL, patients treated with nilotinib generally reported higher satisfaction levels than did those treated with imatinib or dasatinib. When stratified by age or duration of TKI treatment, patients aged <60 years or those with a treatment duration of ≥1 year exhibited better satisfaction levels. Conclusion: Survival outcomes were not affected by history of TKI treatment. Nilotinib is favorable for HRQoL but increases the risk of serious CVEs in patients with vascular risk factors.

1.
O’Brien
SG
,
Guilhot
F
,
Larson
RA
,
Gathmann
I
,
Baccarani
M
,
Cervantes
F
, et al
.
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
.
N Engl J Med
.
2003
;
348
(
11
):
994
1004
.
2.
Druker
BJ
,
Guilhot
F
,
O'Brien
SG
,
Gathmann
I
,
Kantarjian
H
,
Gattermann
N
, et al
.
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
.
N Engl J Med
.
2006
;
355
(
23
):
2408
17
.
3.
Hochhaus
A
,
Saglio
G
,
Hughes
TP
,
Larson
RA
,
Kim
DW
,
Issaragrisil
S
, et al
.
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
.
Leukemia
.
2016
;
30
(
5
):
1044
54
.
4.
Cortes
JE
,
Saglio
G
,
Kantarjian
HM
,
Baccarani
M
,
Mayer
J
,
Boqué
C
, et al
.
Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial
.
J Clin Oncol
.
2016
;
34
(
20
):
2333
40
.
5.
Bower
H
,
Björkholm
M
,
Dickman
PW
,
Höglund
M
,
Lambert
PC
,
Andersson
TM
.
Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population
.
J Clin Oncol
.
2016
;
34
(
24
):
2851
7
.
6.
Network
NCC
.
Myeloproliferative neoplasms (version 2.2021)
.
2021
Available from: https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf
7.
Hochhaus
A
,
Larson
RA
,
Guilhot
F
,
Radich
JP
,
Branford
S
,
Hughes
TP
, et al
.
Long-term outcomes of imatinib treatment for chronic myeloid leukemia
.
N Engl J Med
.
2017
;
376
(
10
):
917
27
.
8.
Network NCC. Chronic myeloid leukemia. Version 3.2022
2022
.
9.
Etienne
G
,
Guilhot
J
,
Rea
D
,
Rigal-Huguet
F
,
Nicolini
F
,
Charbonnier
A
, et al
.
Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia
.
J Clin Oncol
.
2017
;
35
(
3
):
298
305
.
10.
Saussele
S
,
Richter
J
,
Guilhot
J
,
Gruber
FX
,
Hjorth-Hansen
H
,
Almeida
A
, et al
.
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
.
Lancet Oncol
.
2018
;
19
(
6
):
747
57
.
11.
Rea
D
,
Nicolini
FE
,
Tulliez
M
,
Guilhot
F
,
Guilhot
J
,
Guerci-Bresler
A
, et al
.
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
.
Blood
.
2017
;
129
(
7
):
846
54
.
12.
Hahn
EA
,
Glendenning
GA
,
Sorensen
MV
,
Hudgens
SA
,
Druker
BJ
,
Guilhot
F
, et al
.
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study
.
J Clin Oncol
.
2003
;
21
(
11
):
2138
46
.
13.
Sokal
JE
,
Cox
EB
,
Baccarani
M
,
Tura
S
,
Gomez
GA
,
Robertson
JE
, et al
.
Prognostic discrimination in “good-risk” chronic granulocytic leukemia
.
Blood
.
1984
;
63
(
4
):
789
99
.
14.
Hasford
J
,
Pfirrmann
M
,
Hehlmann
R
,
Allan
NC
,
Baccarani
M
,
Kluin-Nelemans
JC
, et al
.
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group
.
J Natl Cancer Inst
.
1998
;
90
(
11
):
850
8
.
15.
Hasford
J
,
Baccarani
M
,
Hoffmann
V
,
Guilhot
J
,
Saussele
S
,
Rosti
G
, et al
.
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
.
Blood
.
2011
;
118
(
3
):
686
92
.
16.
Trotti
A
,
Colevas
AD
,
Setser
A
,
Rusch
V
,
Jaques
D
,
Budach
V
, et al
.
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment
.
Semin Radiat Oncol
.
2003
;
13
(
3
):
176
81
.
17.
Baccarani
M
,
Cortes
J
,
Pane
F
,
Niederwieser
D
,
Saglio
G
,
Apperley
J
, et al
.
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
.
J Clin Oncol
.
2009
;
27
(
35
):
6041
51
.
18.
Baccarani
M
,
Deininger
MW
,
Rosti
G
,
Hochhaus
A
,
Soverini
S
,
Apperley
JF
, et al
.
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
.
Blood
.
2013
;
122
(
6
):
872
84
.
19.
EORTC
.
EORTC quality of life questionnaires
.
20.
Yun
YH
,
Park
YS
,
Lee
ES
,
Bang
SM
,
Heo
DS
,
Park
SY
, et al
.
Validation of the Korean version of the EORTC QLQ-C30
.
Qual Life Res
.
2004
;
13
(
4
):
863
8
.
21.
Fayers
PMAN
,
Bjordal
K
,
Groenvold
M
,
Curran
D
,
Bottomley
A
;
on behalf of the EORTC Quality of Life Group
The EORTC QLQ-C30 scoring manual
. 3rd ed.
Brussels
:
European Organisation for Research and Treatment of Cancer
;
2001
.
22.
Morgan
CJ
.
Landmark analysis: a primer
.
J Nucl Cardiol
.
2019
;
26
(
2
):
391
3
.
23.
Pfirrmann
M
,
Hochhaus
A
,
Lauseker
M
,
Saussele
S
,
Hehlmann
R
,
Hasford
J
.
Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia
.
Leukemia
.
2011
;
25
(
9
):
1433
8
.
24.
Pfirrmann
M
,
Lauseker
M
,
Hoffmann
VS
,
Hasford
J
.
Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death
.
Ann Hematol
.
2015
;
94
(
Suppl 2
):
S209
18
.
25.
Kantarjian
HM
,
Hughes
TP
,
Larson
RA
,
Kim
DW
,
Issaragrisil
S
,
le Coutre
P
, et al
.
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
.
Leukemia
.
2021
;
35
(
2
):
440
53
.
26.
Yeung
DT
,
Osborn
MP
,
White
DL
,
Branford
S
,
Braley
J
,
Herschtal
A
, et al
.
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
.
Blood
.
2015
;
125
(
6
):
915
23
.
27.
Cortes
JE
,
De Souza
CA
,
Ayala
M
,
Lopez
JL
,
Bullorsky
E
,
Shah
S
, et al
.
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial
.
Lancet Haematol
.
2016
;
3
(
12
):
e581
91
.
28.
Cortes
JE
,
Jiang
Q
,
Wang
J
,
Weng
J
,
Zhu
H
,
Liu
X
, et al
.
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
.
Leukemia
.
2020
;
34
(
8
):
2064
73
.
29.
Cortes
JE
,
Lipton
JH
,
Miller
CB
,
Busque
L
,
Akard
LP
,
Pinilla-Ibarz
J
, et al
.
Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH study
.
Clin Lymphoma Myeloma Leuk
.
2016
;
16
(
5
):
286
96
.
30.
Kim
DW
,
Saussele
S
,
Williams
LA
,
Mohamed
H
,
Rong
Y
,
Zyczynski
T
, et al
.
Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study
.
Ann Hematol
.
2018
;
97
(
8
):
1357
67
.
31.
Steegmann
JL
,
Baccarani
M
,
Breccia
M
,
Casado
LF
,
García-Gutiérrez
V
,
Hochhaus
A
, et al
.
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
.
Leukemia
.
2016
;
30
(
8
):
1648
71
.
32.
Caocci
G
,
Mulas
O
,
Annunziata
M
,
Luciano
L
,
Bonifacio
M
,
Orlandi
EM
, et al
.
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: identification of risk factors and the role of prophylaxis
.
Am J Hematol
.
2018
;
93
(
7
):
E159
61
.
33.
Giles
FJ
,
Mauro
MJ
,
Hong
F
,
Ortmann
CE
,
McNeill
C
,
Woodman
RC
, et al
.
Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis
.
Leukemia
.
2013
;
27
(
6
):
1310
5
.
34.
Lassila
M
,
Allen
TJ
,
Cao
Z
,
Thallas
V
,
Jandeleit-Dahm
KA
,
Candido
R
, et al
.
Imatinib attenuates diabetes-associated atherosclerosis
.
Arterioscler Thromb Vasc Biol
.
2004
;
24
(
5
):
935
42
.
35.
Wang
X
,
Roy
A
,
Hochhaus
A
,
Kantarjian
HM
,
Chen
TT
,
Shah
NP
.
Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study
.
Clin Pharmacol
.
2013
;
5
:
85
97
.
36.
Rousselot
P
,
Mollica
L
,
Guilhot
J
,
Guerci
A
,
Nicolini
FE
,
Etienne
G
, et al
.
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients
.
Br J Haematol
.
2021
;
194
(
2
):
393
402
.
37.
Naqvi
K
,
Jabbour
E
,
Skinner
J
,
Anderson
K
,
Dellasala
S
,
Yilmaz
M
, et al
.
Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia
.
Cancer
.
2020
;
126
(
1
):
67
75
.
38.
Murai
K
,
Ureshino
H
,
Kumagai
T
,
Tanaka
H
,
Nishiwaki
K
,
Wakita
S
, et al
.
Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial
.
Lancet Haematol
.
2021
;
8
(
12
):
e902
11
.
39.
Gotay
CC
,
Kawamoto
CT
,
Bottomley
A
,
Efficace
F
.
The prognostic significance of patient-reported outcomes in cancer clinical trials
.
J Clin Oncol
.
2008
;
26
(
8
):
1355
63
.
40.
Efficace
F
,
Gaidano
G
,
Breccia
M
,
Voso
MT
,
Cottone
F
,
Angelucci
E
, et al
.
Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study
.
Lancet Oncol
.
2015
;
16
(
15
):
1506
14
.
41.
Palmer
J
,
Chai
X
,
Pidala
J
,
Inamoto
Y
,
Martin
PJ
,
Storer
B
, et al
.
Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease
.
Blood
.
2016
;
127
(
1
):
160
6
.
42.
Shacham Abulafia
A
,
Shemesh
S
,
Rosenmann
L
,
Berger
T
,
Leader
A
,
Sharf
G
, et al
.
Health-related quality of life in patients with chronic myeloid leukemia treated with first- versus second-generation tyrosine kinase inhibitors
.
J Clin Med
.
2020
;
9
(
11
):
3417
.
43.
Guérin
A
,
Chen
L
,
Ionescu-Ittu
R
,
Marynchenko
M
,
Nitulescu
R
,
Hiscock
R
, et al
.
Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase
.
Curr Med Res Opin
.
2014
;
30
(
11
):
2317
28
.
44.
Efficace
F
,
Stagno
F
,
Iurlo
A
,
Breccia
M
,
Cottone
F
,
Bonifacio
M
, et al
.
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy
.
Leukemia
.
2020
;
34
(
2
):
488
98
.
45.
Hughes
TP
,
Mauro
MJ
,
Cortes
JE
,
Minami
H
,
Rea
D
,
DeAngelo
DJ
, et al
.
Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure
.
N Engl J Med
.
2019
;
381
(
24
):
2315
26
.
46.
Réa
D
,
Mauro
MJ
,
Boquimpani
C
,
Minami
Y
,
Lomaia
E
,
Voloshin
S
, et al
.
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs
.
Blood
.
2021
;
138
(
21
):
2031
41
.
47.
Yeung
DT
,
Shanmuganathan
N
,
Hughes
TP
.
Asciminib: a new therapeutic option in chronic-phase CML with treatment failure
.
Blood
.
2022
;
139
(
24
):
3474
9
.
You do not currently have access to this content.